Open company graph database — free web & API
Login

Spera Pharma Co., Ltd.

スペラファーマ株式会社SPERA PHARMA, Inc.Aliasスぺラファーマ株式会社Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
249
Related companies
7
§01

Basic information

BASIC
Head office
2-17-85 Juso-honcho, Yodogawa-ku, Osaka 532-0024, Japan (Inside Takeda Pharmaceutical Company Osaka Factory)
Chief executive
Keitaro Iwaki
Capital
310,000,000  (3 100 million)
Employees (non-consolidated)
Employees (consolidated)
249 people
Start date
2017-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

6
CMC research and development and manufacturing outsourcing business for pharmaceuticalsServices related to active pharmaceutical ingredient process developmentServices related to formulationServices related to analysis and testingIntroduction of technology and achievementsIntroduction of facilities
§04

Related companies

7 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Speranexus Corporation
Group Subsidiary
JITSUBO Co., Ltd.
Group Subsidiary
Bushu Pharmaceuticals Ltd.
Group
Iwaki Pharmaceuticals Sakura Factory Co., Ltd.
Group Subsidiary
イワキグループ
Group
Takeda Pharmaceutical Company, Limited
Group
Astea Holdings Co., Ltd.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

2 EVENTS

Established: April 2017Sources

Business start: July 2017Sources

§07

News

24 ARTICLES

[External Lecture] 12/15: Interfax Conference Toyama 2026Sources

Dr. Shūji Yamazaki, Director of the Osaka Research Center at Spear Pharma Co., Ltd., will give a lecture on effective CDMO utilization to accelerate pharmaceutical development at the Interfax Conference Toyama 2026, held on December 15, 2026, at the Toyama International Convention Center. After the lecture, a networking session is scheduled, providing an opportunity for business card exchanges and information sharing.

Lecture and Exhibition at the MicroED/3D ED Users Meeting on 11/5Sources

Spel Pharma will exhibit at the second MicroED/3D ED Users Meeting, held on November 5, 2026, at Asakusa Bridge Hürik Hall. Our pharmaceutical research institute's Keiyou Nakai will give an invited talk titled "After Solving the Structure with MicroED" on the same day. Admission is free, and the application deadline is October 31.

Panel Presentation at the Formulation and Particle Design SymposiumSources

Spefara Pharma will exhibit at the 43rd Formulation and Particle Design Symposium, held at the Fukuoka International Conference Center on November 5-6, 2026. On November 6, Yusuke Ichihara from the Formulation Technology Research Institute will give a panel presentation titled "Accelerating Development with DIC Utilization." The talk will cover points of DIC utilization and case studies on handling small-API and difficult-to-fill active pharmaceutical ingredients.

MicroED Talk at Medicinal Chemistry SymposiumSources

Spera Pharma will exhibit at the 43rd Medicinal Chemistry Symposium, to be held at Kyoto Terrsa from November 11 to 13, 2026. On November 13, Hiroaki Nakai of the company’s Pharmaceutical Research Institute will give an invited lecture titled “From Nanocrystals to Drug Development: The Structural Analysis Revolution Brought by MicroED.” The lecture will cover the principles and features of MicroED, as well as salt, co-crystal, and crystal polymorph analysis; evaluation of crystalline phases in pharmaceutical formulations; and absolute configuration determination.

Spera Pharma Research Published in International JournalSources

A collaborative study by researchers at Spera Pharma Co., Ltd. was published in Chemistry – An Asian Journal. It describes a new [3+2+2] cycloaddition using bis(trimethylsilyl)cyclopropanone and diynes, with potential applications in synthesizing bioactive substances and functional molecules.

Spera Pharma to Exhibit at BioJapan 2026Sources

Spera Pharma will exhibit at BioJapan 2026 in Yokohama from October 7 to 9, 2026. Visit booth D-06; advance registration is required. The company will introduce biopharmaceutical analysis and its global collaboration network.

Spera Pharma to Exhibit at Discovery & Development US 2026Sources

Spera Pharma will exhibit at Discovery & Development US 2026, held October 12–13, 2026, at the Hilton San Diego Bayfront in San Diego, California. Yoichiro Ishimaru will speak on “Preformulation and Solid Form Technologies Utilizing MicroED as a Game Changer for API Characterization.” The presentation is scheduled for October 12, 12:50–1:15 p.m. PDT.

Researchers' Paper Published in Journal of Natural ProductsSources

On September 15, 2026, a paper by Hiroaki Nakai and Kuniriki Miki of our pharmaceutical research laboratory was published in the American Chemical Society journal Journal of Natural Products. Titled 'Nitrogen-Functionalized Amphilectane-Type Diterpenoids,' it reports structural analysis and biological activity evaluation of novel diterpenoids with anti-HBV activity derived from marine organisms. Structural analysis of microcrystals using MicroED contributed to the research.

Challenges in Quality Control of Nucleic Acid Therapeutics and Fundamental ApproachesSources

This Supera webinar explains why quality control of nucleic acid therapeutics is challenging and outlines fundamental approaches. It will be useful to those interested in using analytical results and developing quality assessment strategies.

Spera Webinar on Biopharmaceutical Development and Quality Control, September 28Sources

This webinar will be held on Microsoft Teams on September 28, 2026, from 1:00 to 1:45 p.m. It has two parts covering process development and aseptic manufacturing strategies for biopharmaceutical injections, as well as analytical methods and quality control. It is recommended for people planning manufacturing strategies early in development and those interested in aseptic manufacturing risks, method selection, and quality assessment.

§08

Public records

GOV
National Tax Agency basic information7120001205323
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
スペラファーマ株式会社
Trade name (kana)
スペラファーマ
Name in English
Corporation type
301
Address
〒532-0024 大阪府大阪市淀川区十三本町2丁目17番85号
Postal code
5320024
Prefecture code
27
City code
123
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2017-05-01
Update date
2020-03-04
Change date
2017-05-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
11
Correction type
1
Trade name image ID
Address image ID
Sequence number
4317030
METI gBizINFO7120001205323
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7120001205323
Trade name
スペラファーマ株式会社
Trade name (kana)
スペラファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市淀川区十三本町2丁目17番85号
Postal code
5320024
Prefecture
大阪府
Prefecture code
27
City or district
大阪市淀川区
City code
123
Street address
十三本町2丁目17番85号
Organisation type
301
Processing type
11
Correction type
1
Status
Representative
代表取締役 岩城 慶太郎
Capital
Employees
245
Employees (male)
155
Employees (female)
75
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
2017-04-20
Unified government qualification - grade
C||B|
Unified government qualification - business items
122|129|303|315
Update date
2020-03-04
Key information
7120001205323
§09

Sources & updates

SOURCES
↑